Merck & Co and UnitedHealth Group are set to exit the urologic cancer diagnostics technology provider in an acquisition by Veracyte.
Genomic testing technology developer Veracyte has agreed to buy Decipher Biosciences, a US-based peer backed by pharmaceutical group Merck & Co and healthcare provider UnitedHealth Group, for $600m.
The deal will entail Veracyte paying roughly 40% of the sum in cash and the remainder in stock consideration, subject to purchase price adjustments. It came in the wake of Decipher filing for an initial public offering in recent weeks.
Decipher was founded in 2008 as GenomeDx Biosciences, and has built…
